Boy home after rare stem cell treatment

Feb 12, 2008

Balloons and signs greeted 2-year-old Caden Ledbetter's return from the hospital following a rare stem cell cancer treatment, a Dallas newspaper said.

Doctors with the Medical City Dallas Hospital released Caden Monday following a two-month treatment for neuroblastoma, a cancer of the nervous system.

Doctors used chemotherapy to treat the cancer and then used stem cells from Caden's umbilical cord to rebuild his immune system, The Dallas Morning News said Tuesday. The treatment is so rare doctors are unsure whether the cancer will stay in remission or develop again from the umbilical cells.

"We're not talking about his being cured of his neuroblastoma right now," said Dr. Joel Weinthal who treated the boy. "It's certainly a very positive thing that he gets to go home from the hospital but he has a long road ahead of him."

The Ledbetters put air purifiers and a new circulation system in their house to help protect Caden's new immune system and he will undergo more radiation treatments for cancer.

His mother told the Morning News that Caden didn't talk to anyone at the hospital "and everything was 'No, don't touch me,'" but she added that, "Now we're almost back to the Caden that we know."

Copyright 2008 by United Press International

Explore further: Patient resources for ventricular assist devices info suboptimal

add to favorites email to friend print save as pdf

Related Stories

Heavy rains leave 22 dead in Nicaragua

3 hours ago

Days of torrential rains in Nicaragua left 22 people dead and left homeless more than 32,000 others, according to an official report Saturday.

New iPad cellular models have Apple SIM flexibility

3 hours ago

Cellular-enabled iPad models are under a new paradigm, said AppleInsider, regarding the Apple SIM. Apple's newest iPad models with cellular connectivity use a SIM card which tech sites said could eventually ...

Recommended for you

70-gene signature not cost-effective in breast cancer

Oct 18, 2014

(HealthDay)—For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published ...

User comments : 0